LRA Brings Encouraging News from European Rheumatology Meeting
June 2, 2022
The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS)...
lupus therapeutics
Lupus Nephritis: A Major Focus at the Lupus Research Alliance
Updated March, 2022
Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the...
Encouraging Results with Obinutuzumab for Lupus Nephritis
February 13, 2022
The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive...
Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research
NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and clinical affiliate Lupus Therapeutics (LT) announced two major initiatives improving representation...
Tips on How Men Can Cope with Lupus from HSS Professional
October 7, 2021
In recognition of Hispanic Heritage Month, we are sharing a blog post from Latina professional Priscilla Toral,...
LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020
30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways
Results from...
Lupus Clinical Trials Redefined: You Make the Difference
Lupus Clinical Trials Redefined: You Make the Difference
Lupus Clinical Trials Virtual Fair
October 17, 2020
10:00 am to 1:00 pm ET
Register...
LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis
September 16, 2020
NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s...
2018 LRA Lupus Insight Prize Recipient Receives $15 M Grant from NIH to Study Lupus Effects on the Brain
July 27, 2020
The Lupus Research Alliance congratulates 2018 Lupus Insight Prize recipient Betty Diamond, MD and the Feinstein Institutes...
New Study Presents Strategies That Helped African-Americans Take Part In Lupus Trials
June 22, 2020
African-Americans are more likely to develop lupus than Caucasians, but less likely to take part in clinical...
New LRA-Supported Study Discovers STAT1, a Highly Specific Target for Potential New Therapy
April 23, 2020
A new study supported by the Lupus Research Alliance discovered a way that harmful immune responses in...
Lupus Therapeutics, Affiliate of Lupus Research Alliance, Developing a Study Focused on Lupus Patients and COVID-19
New York, NY, April 7, 2020 – Lupus Therapeutics, the clinical trial affiliate of the Lupus Research Alliance (LRA),...